
    
      This is a dose finding trial. Totally 120 mild-moderate essential hypertension patients will
      be enrolled. All the patients will be randomized (1:1:1:1) into four groups (SPH3127 50mg,
      SPH3127 100mg, SPH3127 200mg and placebo).

      The trial has three phases: the screening phase, the leading phase and the treating phase.

      The primary endpoints are the changes of DBP and SBP compared to the baseline after 8 weeks
      of treatment.

      All the adverse events are required to be collected for safety analyzing.
    
  